Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: ?
Life Threatening? No
Write-up: This is a spontaneous report from a contactable consumer (patient''s wife), based on information received by Pfizer from BioNTech (control number: 60390), licensed party for BNT162B2 (Comirnaty). A 64-year-old male patient received the first dose of BNT162B2 (Comirnaty, solution for injection, lot# EX8680), at the age of 64, via an unknown route, on May 11, 2021, single dose, for COVID-19 immunisation. No medical history or concomitant medications provided. Since Jun 1, 2021, patient has unilateral facial paralysis (medically significant). He can''t shut his eye completely, eyelid problems (non-serious). The patient visited the doctor. He was given cortisone tablets and eye ointment. The patient has not recovered from the events.
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166